Yahoo
Tokyo - Delayed Quote JPY

Chugai Pharmaceutical Co., Ltd. (4519.T)

6,822.00 +169.00 (+2.54%)
At close: October 30 at 3:30:00 PM GMT+9
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
1,414,375,000
1,257,941,000
1,170,611,000
1,111,367,000
1,259,726,000
Cost of Revenue
403,660,000
363,690,000
339,409,000
413,306,000
476,251,000
Gross Profit
1,010,716,000
894,251,000
831,201,000
698,061,000
783,475,000
Operating Expense
319,140,000
295,418,000
289,199,000
258,887,000
250,167,000
Operating Income
691,576,000
598,833,000
542,002,000
439,174,000
533,308,000
Net Non Operating Interest Income Expense
7,885,000
-1,026,000
1,032,000
4,647,000
-9,000
Pretax Income
703,811,000
597,807,000
543,034,000
443,821,000
531,166,000
Tax Provision
200,098,000
163,794,000
155,717,000
118,349,000
156,737,000
Net Income Common Stockholders
503,712,000
434,012,000
387,317,000
325,472,000
374,429,000
Diluted NI Available to Com Stockholders
503,712,000
434,012,000
387,317,000
325,472,000
374,429,000
Basic EPS
306.10
263.73
235.39
197.83
227.64
Diluted EPS
306.09
263.72
235.36
197.80
227.57
Basic Average Shares
1,645,734.27
1,645,661.61
1,645,426.74
1,645,208.82
1,645,208.82
Diluted Average Shares
1,645,799.66
1,645,727
1,645,636.47
1,645,498.98
1,645,335.50
Total Operating Income as Reported
691,576,000
598,833,000
542,002,000
439,174,000
533,309,000
Total Expenses
722,800,000
659,108,000
628,608,000
672,193,000
726,418,000
Net Income from Continuing & Discontinued Operation
503,712,000
434,012,000
387,317,000
325,472,000
374,429,000
Normalized Income
503,712,000
434,012,000
387,317,000
325,472,000
374,429,000
Interest Income
--
--
5,000
--
--
Interest Expense
--
207,000
--
27,000
61,000
Net Interest Income
7,885,000
-1,026,000
1,032,000
4,647,000
-9,000
EBIT
692,570,000
598,014,000
542,002,000
443,848,000
531,227,000
EBITDA
692,570,000
598,014,000
542,002,000
443,848,000
531,227,000
Reconciled Cost of Revenue
403,660,000
363,690,000
339,409,000
413,306,000
476,251,000
Net Income from Continuing Operation Net Minority Interest
503,712,000
434,012,000
387,317,000
325,472,000
374,429,000
Normalized EBITDA
692,570,000
598,014,000
542,002,000
443,848,000
531,227,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: